Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Issue 6 (14th March 2018)
- Record Type:
- Journal Article
- Title:
- Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Issue 6 (14th March 2018)
- Main Title:
- Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers
- Authors:
- Chantepie, Sylvain P.
Garciaz, Sylvain
Tchernonog, Emmanuelle
Peyrade, Frederic
Larcher, Marie‐Virginie
Diouf, Momar
Fornecker, Luc‐Mathieu
Houot, Roch
Gastinne, Thomas
Soussain, Carole
Malak, Sandra
Lemal, Richard
Delette, Caroline
Ibrahim, Ahmad
Gac, Anne‐Claire
Reboursière, Emilie
Vilque, Jean‐Pierre
Bekadja, Mohamed‐Amine
Casasnovas, Rene‐Olivier
Gressin, Remy
Guidez, Stéphanie
Coso, Diane
Herbaux, Charles
Yakoub‐Agha, Ibrahim
Bouabdallah, Krimo
Durot, Eric
Damaj, Gandhi - Abstract:
- Abstract: Carmustine shortage has led to an increase use of alternative conditioning regimens prior to autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine‐based (BeEAM). The aim of this study was to evaluate the safety of the BeEAM regimen in a large cohort of patients. A total of 474 patients with a median age of 56 years were analyzed. The majority of patients had diffuse large B‐cell lymphoma (43.5%). Bendamustine was administered at a median dose of 197 mg/m 2 /day (50‐250) on days‐7 and −6. The observed grade 1‐4 toxicities included mucositis (83.5%), gastroenteritis (53%), skin toxicity (34%), colitis (29%), liver toxicity (19%), pneumonitis (5%), and cardiac rhythm disorders (4%). Nonrelapse mortality (NRM) was reported in 3.3% of patients. Acute renal failure (ARF) was reported in 132 cases (27.9%) (G ≥2; 12.3%). Organ toxicities and death were more frequent in patients with post conditioning renal failure. In a multivariate analysis, pretransplant chronic renal failure, bendamustine dose >160 mg/m 2 and age were independent prognostic factors for ARF. Pretransplant chronic renal failure, hyperhydration volume, duration of hyperhydration, and etoposide dose were predictive factors of NRM. A simple, four‐point scoring system can stratify patients by levels of risk for ARF and may allow for a reduction in the bendamustine dose to avoid toxicity. Drugs shortage may have dangerous consequences. Prospective, comparative studies areAbstract: Carmustine shortage has led to an increase use of alternative conditioning regimens prior to autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine‐based (BeEAM). The aim of this study was to evaluate the safety of the BeEAM regimen in a large cohort of patients. A total of 474 patients with a median age of 56 years were analyzed. The majority of patients had diffuse large B‐cell lymphoma (43.5%). Bendamustine was administered at a median dose of 197 mg/m 2 /day (50‐250) on days‐7 and −6. The observed grade 1‐4 toxicities included mucositis (83.5%), gastroenteritis (53%), skin toxicity (34%), colitis (29%), liver toxicity (19%), pneumonitis (5%), and cardiac rhythm disorders (4%). Nonrelapse mortality (NRM) was reported in 3.3% of patients. Acute renal failure (ARF) was reported in 132 cases (27.9%) (G ≥2; 12.3%). Organ toxicities and death were more frequent in patients with post conditioning renal failure. In a multivariate analysis, pretransplant chronic renal failure, bendamustine dose >160 mg/m 2 and age were independent prognostic factors for ARF. Pretransplant chronic renal failure, hyperhydration volume, duration of hyperhydration, and etoposide dose were predictive factors of NRM. A simple, four‐point scoring system can stratify patients by levels of risk for ARF and may allow for a reduction in the bendamustine dose to avoid toxicity. Drugs shortage may have dangerous consequences. Prospective, comparative studies are needed to confirm the toxicity/efficacy extents from this conditioning regimen compared to other types of high dose therapy. … (more)
- Is Part Of:
- American journal of hematology. Volume 93:Issue 6(2018:Jun.)
- Journal:
- American journal of hematology
- Issue:
- Volume 93:Issue 6(2018:Jun.)
- Issue Display:
- Volume 93, Issue 6 (2018)
- Year:
- 2018
- Volume:
- 93
- Issue:
- 6
- Issue Sort Value:
- 2018-0093-0006-0000
- Page Start:
- 729
- Page End:
- 735
- Publication Date:
- 2018-03-14
- Subjects:
- Hematology -- Periodicals
616.15 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-8652 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/ajh.25077 ↗
- Languages:
- English
- ISSNs:
- 0361-8609
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0824.800000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 18772.xml